This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Alimera, pSivida Eye Drug Warrants FDA Approval On Third Try

NEW YORK (TheStreet) -- Alimera (ALIM) and pSivida (PSDV) have an upcoming FDA drug approval decision date on Oct. 17 for the use of Iluvien to treat chronic diabetic macular edema. The FDA has already rejected Iluvien twice but the companies have a better shot with approval on this third trip through the agency. An Iluvien approval is good for both companies, obviously, but perhaps more so immediately for pSivida because it will receive a $25 million milestone payment. Right now, that equates to about 20 percent of pSivida's current market cap.

Let's review why Iluvien is more likely to be approved this time.

In its last Complete Response Letter rejecting Iluvien, FDA told Alimera that it would "need to conduct two additional clinical trials to demonstrate that the product is safe and effective for the proposed indication." Despite what seems like fairly specific guidance, Alimera did not run the requested clinical trials. Normally, ignoring FDA's advice would be disastrous, but in this case, perhaps not.

The key issue raised by the FDA about Iluvien was not the drug's efficacy. The phase III trial demonstrated that 28.7 percent (low dose Iluvien) and 27.8 percent (high dose Iluvien) of the treated diabetic macular edema (DME) patients gained more than 15 letters of vision versus 18.9 percent in control arm -- a statistically significant difference. The Iluvien benefit was even more pronounced in a pre-planned subset of patients with DME for more than 3 years. In this group, 34.0 percent (low dose Iluvien) and 28.8 percent (high dose Iluvien) gained more than 15 letters of vision versus 13.4 percent for the control arm.

The FDA's bigger concern about Iluvien focused on side effects. "The risks of adverse reactions shown for Iluvien in the FAME Study were significant and were not offset by the benefits demonstrated by Iluvien in these clinical trials," said Alimera, quoting from the FDA's Complete Response Letter. Two key adverse events tied to Iluvien caused most of the problem. 1) Cataract extraction had to be done in 41.1 percent of the low-dose patients, 50.9 percent of the high-dose patients and only 7 percent of the sham group; and 2) more Iluvien patients require intraocular pressure-reducing interventions (8.1 percent high-dose versus 3.7 percent low-dose versus 0.5 percent sham.)

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,105.22 +18.59 0.11%
S&P 500 1,990.70 +3.69 0.19%
NASDAQ 4,481.3540 +7.6570 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs